| Zilbrysq (zilucoplan) / UCB |
2018-003956-19: Study of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
|
| Not yet recruiting | 3 | 40 | Europe | Zilucoplan, RA101495, Solution for injection | Ra Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc. | Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT05514873: An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors |
|
|
| Completed | 3 | 26 | US | zilucoplan (RA101495) | UCB Biopharma SRL | Generalized Myasthenia Gravis | 03/24 | 10/24 | | |
NCT06471361: A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis |
|
|
| Active, not recruiting | 3 | 31 | Europe, US | Zilucoplan, RA101495 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 01/25 | 01/25 | | |
ziMyG+, NCT06435312: An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis |
|
|
| Enrolling by invitation | 3 | 8 | Europe, US, RoW | Zilucoplan, RA101495 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 10/27 | 12/27 | | |
| Active, not recruiting | 3 | 200 | Europe, Canada, Japan, US | zilucoplan (RA101495) | UCB Biopharma SRL | Generalized Myasthenia Gravis | 06/26 | 06/26 | | |
NCT04436497: HEALEY ALS Platform Trial - Regimen A Zilucoplan |
|
|
| Completed | 2/3 | 162 | US | Zilucoplan, Matching Placebo | Merit E. Cudkowicz, MD, Ra Pharmaceuticals | Amyotrophic Lateral Sclerosis | 04/22 | 05/22 | | |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
NCT06055959: A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis |
|
|
| Recruiting | 2/3 | 8 | Europe, US, RoW | Zilucoplan, RA101495 | UCB Biopharma SRL | Generalized Myasthenia Gravis | 11/26 | 12/26 | | |
2020-001736-95: A Phase 2 Study for the Treatment of COVID 19 in Hospitalised Patients |
|
|
| Ongoing | 2 | 825 | Europe | Bemcentinib, MEDI3506, acalabrutinib, Zilucoplan, Heparin, TD139, BGB324, MEDI3506, ACP-196, Capsule, hard, Solution for injection, Solution for injection in pre-filled syringe, Inhalation powder, Heparin | University Hospital Southampton NHS Foundation Trust | COVID 19, COVID 19, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-001497-29: A Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy |
|
|
| Not yet recruiting | 2 | 24 | Europe | Zilucoplan, Solution for injection in pre-filled syringe | Ra Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc. | Immune-Mediated Necrotizing Myopathy, Immune-Mediated Necrotizing Myopathy, Diseases [C] - Nervous System Diseases [C10] | | | | |
ACTRN12615001143516: A first in human study assessing the safety and pharmacokinetics (blood levels) of RA101495. |
|
|
| Recruiting | 1 | 40 | Rest Of World | RA101495 | Ra Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc. | Paroxysmal nocturnal hemoglobinuria | | | | |
|
|
NCT06511076: A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants |
|
|
| Completed | 1 | 14 | Europe | Zilucoplan, RA101495 | UCB Biopharma SRL | Healthy Volunteers | 11/24 | 11/24 | | |
